Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
|
|
Arcturus Therapeutics Holdings Inc. (ARCT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/20/2019 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 18, 2019 ARCTURUS THERAPEUTICS HOLDINGS INC. Delaware 001-38942 32-0595345 10628 Science Center Drive, Suite 250 San Diego, California 92121 Registrant's telephone number, including area code: 900-2660 Arcturus Therapeutics Ltd. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d...",
"Registration Rights Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Equity Purchase Agreement, between the Company and Ultragenyx Pharmaceutical Inc",
"Third Amendment, to Research Collaboration and License Agreement, as amended on October 17, 2017 and April 20, 2018, between the Company and Ultragenyx Pharmaceutical Inc",
"Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases" |
|
|
|